Quantitative measurement of IgG to SARS-CoV-2 antigens using monoclonal antibody-based enzyme-linked immunosorbent assays.
Quantitative measurement of IgG to SARS-CoV-2 antigens using monoclonal antibody-based enzyme-linked immunosorbent assays.
复制标题
DOI：
10.1002/cti2.1369
复制
发表时间：
2022
影响因子：
5.8
通讯作者：
Raulf M
中科院分区：
文献类型：
--
作者：
Sander I;Kespohl S;Zahradnik E;Göcke P;Hosbach I;Herrmann BL;Brüning T;Raulf M
对SARS-CoV-2抗原的体液免疫应答进行标准化定量分析可能有助于估计免疫的程度和持续时间。目的是开发酶联免疫吸附试验（ELISA），用于定量抗SARS-CoV-2抗原的人IgG抗体。基于抗人IgG和重组SARS-CoV-2抗原（Spike-S1和Nucleocapsid）的单克隆抗体开发了酶联免疫吸附试验。使用WHO 67/086免疫球蛋白和WHO 20/136 SARS-CoV-2参考品进行标准化。分析了COVID-19阳性受试者（n = 144）、大流行前对照组（n = 135）和接种BioNTech-Pfizer BNT 162 b2疫苗的个体（n = 48）的血清。还使用EuroImmun SARS-CoV-2-ELISA和Thermo Fisher的定量S1特异性荧光酶免疫测定法（FEIA）检测了研究组血清。由于ELISA结果与两种WHO参考品平行，因此ELISA结果具有可重复性，并可溯源至国际单位。在研究组中，抗S1-IgG浓度中位数为102 BAU mL−1，而接种组在第一次和第二次接种后分别为100和1457 BAU mL−1。在受试者工作特征（ROC）分析中，ELISA的曲线下面积（AUC）为0.965（S1）和0.955（核衣壳），在最大约登指数下，特异性为1（S1）和0.963（核衣壳），灵敏度为0.903（S1）和0.833（核衣壳）。相比之下，商业检测试剂盒（S1-FEIA、S1和核衣壳ELISA EuroImmun）在研究组中的灵敏度分别为0.764、0.875和0.882。用于测定IgG与SARS-CoV-2抗原结合的定量ELISA具有良好的分析和临床性能特征，单位可溯源至国际标准。我们开发了ELISA来定量SARS-CoV-2抗原的IgG水平，具有良好的分析和临床性能，可以使用普通实验室设备进行，提供可追溯到国际标准（IU和BAU）的单位结果，并且可以很容易地适用于定量SARS-CoV-2突变蛋白和其他抗原的IgG。
Standardised quantitative analysis of the humoral immune response to SARS‐CoV‐2 antigens may be useful for estimating the extent and duration of immunity. The aim was to develop enzyme‐linked immunosorbent assays (ELISAs) for the quantification of human IgG antibodies against SARS‐CoV‐2 antigens. Enzyme‐linked immunosorbent assays were developed based on monoclonal antibodies against human IgG and recombinant SARS‐CoV‐2 antigens (Spike‐S1 and Nucleocapsid). The WHO 67/086 immunoglobulin and WHO 20/136 SARS‐CoV‐2 references were used for standardisation. Sera of a study group of COVID‐19‐positive subjects (n = 144), pre‐pandemic controls (n = 135) and individuals vaccinated with BioNTech–Pfizer BNT162b2 vaccine (n = 48) were analysed. The study group sera were also tested using EuroImmun SARS‐CoV‐2‐ELISAs and a quantitative S1‐specific fluorescence enzyme immunoassay (FEIA) from Thermo Fisher. The ELISA results were repeatable and traceable to international units because of their parallelism to both WHO references. In the study group, median anti‐S1‐IgG concentrations were 102 BAU mL−1, compared to 100 and 1457 BAU mL−1 in the vaccination group after first and second vaccination, respectively. The ELISAs achieved an area under the curve (AUC) of 0.965 (S1) and 0.955 (Nucleocapsid) in receiver operating characteristic (ROC) analysis, and a specificity of 1 (S1) and 0.963 (Nucleocapsid) and sensitivity of 0.903 (S1) and 0.833 (Nucleocapsid) at the maximum Youden index. In comparison, the commercial assays (S1‐FEIA, S1 and Nucleocapsid ELISA EuroImmun) achieved sensitivities of 0.764, 0.875 and 0.882 in the study group, respectively. The quantitative ELISAs to measure IgG binding to SARS‐CoV‐2 antigens have good analytical and clinical performance characteristics and units traceable to international standards. We developed ELISAs to quantify IgG levels in response to SARS‐CoV‐2 antigens with good analytical and clinical performance that can be carried out using common laboratory equipment, provide results in units traceable to international standards (IU and BAU) and can be easily adapted to quantify IgG to SARS‐CoV‐2‐mutated proteins and other antigens.
登录
查看更多内容
DOI：
10.1016/j.jcv.2020.104690
发表时间：
2021-01
期刊：
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
影响因子：
--
作者：
Coste AT;Jaton K;Papadimitriou-Olivgeris M;Greub G;Croxatto A
通讯作者：
Croxatto A
影响因子：
5.4
作者：
Figueiredo-Campos P;Blankenhaus B;Mota C;Gomes A;Serrano M;Ariotti S;Costa C;Nunes-Cabaço H;Mendes AM;Gaspar P;Pereira-Santos MC;Rodrigues F;Condeço J;Escoval MA;Santos M;Ramirez M;Melo-Cristino J;Simas JP;Vasconcelos E;Afonso Â;Veldhoen M
通讯作者：
Veldhoen M
影响因子：
16.6
作者：
Bates TA;Leier HC;Lyski ZL;McBride SK;Coulter FJ;Weinstein JB;Goodman JR;Lu Z;Siegel SAR;Sullivan P;Strnad M;Brunton AE;Lee DX;Adey AC;Bimber BN;O'Roak BJ;Curlin ME;Messer WB;Tafesse FG
通讯作者：
Tafesse FG
先前感染状态，定量SARS-COV-2抗尖峰反应对辉瑞-biontech和牛津 - 震中疫苗的反应。
DOI：
10.1016/j.cmi.2021.05.041
发表时间：
2021-10
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Eyre DW;Lumley SF;Wei J;Cox S;James T;Justice A;Jesuthasan G;O'Donnell D;Howarth A;Hatch SB;Marsden BD;Jones EY;Stuart DI;Ebner D;Hoosdally S;Crook DW;Peto TEA;Walker TM;Stoesser NE;Matthews PC;Pouwels KB;Walker AS;Jeffery K
通讯作者：
Jeffery K
影响因子：
2.2
作者：
DomBourian, Melkon G.;Annen, Kyle;Knight, Vijaya
通讯作者：
Knight, Vijaya